Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DAS181 for Severe COVID-19: Compassionate Use

Trial Profile

DAS181 for Severe COVID-19: Compassionate Use

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 06 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DAS 181 (Primary)
  • Indications COVID 2019 infections
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 01 May 2020 Status changed from recruiting to completed.
    • 02 Apr 2020 According to an Ansun Biopharma Media Release, in the first 14 days, the first two patients no longer required supplemental oxygen, and showed stabilized vital signs, increased oxygen saturation, and resolution of infiltrates on chest CT scans. The third patient, who had been a persistent SARS-CoV-2 carrier for more than 33 days, was completely virus-free before the end of the 10-day DAS181 regimen and met all discharge criteria, and the fourth is currently undergoing treatment.
    • 02 Apr 2020 According to an Ansun Biopharma Media Release, Dr. Ke Hu is the principal investigator.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top